$116 Million is the total value of BML Capital Management, LLC's 31 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 300.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIL | Buy | SPDR SER TRbloomberg 1-3 mo | $18,364,000 | +100.8% | 200,000 | +100.0% | 15.87% | +81.7% |
| SGOV | New | ISHARES TR0-3 mnth treasry | $12,572,500 | – | 125,000 | +100.0% | 10.87% | – |
| CYT | New | CYTEIR THERAPEUTICS INC | $5,726,259 | – | 3,146,296 | +100.0% | 4.95% | – |
| ATHA | Buy | ATHIRA PHARMA INC | $4,662,268 | +105.8% | 1,864,907 | +160.9% | 4.03% | +86.1% |
| New | ENLIVEN THERAPEUTICS INC | $4,646,720 | – | 212,179 | +100.0% | 4.02% | – | |
| TALS | New | TALARIS THERAPEUTICS INC | $3,627,430 | – | 1,929,484 | +100.0% | 3.14% | – |
| New | EMBARK TECHNOLOGY INC | $3,611,946 | – | 1,285,390 | +100.0% | 3.12% | – | |
| ORMP | New | ORAMED PHARMACEUTICALS INC | $2,955,917 | – | 1,355,925 | +100.0% | 2.56% | – |
| JNCE | New | JOUNCE THERAPEUTICS INC | $2,012,728 | – | 1,087,961 | +100.0% | 1.74% | – |
| FBRX | Buy | FORTE BIOSCIENCES INC | $1,752,426 | +19.9% | 1,735,075 | +18.7% | 1.52% | +8.5% |
| New | CARISMA THERAPEUTICS INC | $1,275,334 | – | 411,398 | +100.0% | 1.10% | – | |
| New | SURROZEN INC | $899,410 | – | 1,494,037 | +100.0% | 0.78% | – | |
| MIST | Buy | MILESTONE PHARMACEUTICALS IN | $866,800 | +21.6% | 220,000 | +22.2% | 0.75% | +10.0% |
| NXTC | New | NEXTCURE INC | $453,568 | – | 306,465 | +100.0% | 0.39% | – |
| GRPH | New | GRAPHITE BIO INC | $373,113 | – | 152,291 | +100.0% | 0.32% | – |
| NLTX | New | NEOLEUKIN THERAPEUTICS INC | $16,624 | – | 23,749 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-04-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.